Jeffrey Ubben’s ValueAct Continues to Surge Despite its Valeant Stake

The activist firm’s flagship hedge fund is still up for the year despite still holding shares of the embattled drugmaker.

Stephen Taub December 17, 2025

2017-07-alpha-stephen-taub-value-act-valeant-pharmaceuticals-small.jpg

Valeant Pharmaceuticals International headquarters (photo credit: Ron Antonelli/Bloomberg)Who says you can’t make money if you are all in on Valeant Pharmaceuticals International? While hedge funds managed by Bill Ackman’s Pershing

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

develop build:2025-12-17 Login